Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

समान संसाधन

• GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity
  द्वारा: Herter, Sylvia, और अन्य
  प्रकाशित: (2018)
• A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
  द्वारा: Tobinai, Kensei, और अन्य
  प्रकाशित: (2016)
• γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
  द्वारा: Braza, Mounia Sabrina, और अन्य
  प्रकाशित: (2011)
• Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody
  द्वारा: Meneses-Lorente, Georgina, और अन्य
  प्रकाशित: (2015)
• Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
  द्वारा: Cartron, Guillaume, और अन्य
  प्रकाशित: (2016)